Latest:
FGFRi-Related Stomatitis and Dry Mouth Impacting Patient Quality of Life
Many patients with cholangiocarcinoma being treated with FGFRi will experience stomatitis and dry mouth, but there are strategies that can help.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
David Planchard, MD, PhD
David Planchard is a thoracic oncologist and head of the thoracic pathology committee at Gustave Roussy. He is also president of the International Center for Thoracic Cancers (CICT), a health cooperation group combining Gustave Roussy, the Marie-Lannelongue Hospital, and the Paris Saint-Joseph Hospital.
Latest:
Dr. Planchard on the Benefit of Sunvozertinib in EGFR Exon 20–Mutated NSCLC
David Planchard, MD, PhD, discusses the benefit of sunvozertinib in EGFR exon 20–mutated non–small cell lung cancer (NSCLC).
Noha Soror, MD
Noha Soror, MD, is a hematology/oncology fellow at the University of Oklahoma College of Medicine
Latest:
Dr Soror on Patient-Reported Outcomes in Hospitalized Patients With Cancer
Noha Soror, MD, discussed data from an analysis of patient-reported outcomes in from hospitalized patients with cancer.
Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute
Latest:
Dr Davids on Treatment With Pirtobrutinib in CLL/SLL With/Without Prior BCL-2 Inhibitor Exposure
Matthew S. Davids, MD, MMSc, discusses key efficacy results from 2 follow-up analyses of the phase 1/2 BRUIN trial evaluating pirtobrutinib.
Tali Azenkot, MD
Tali Azenkot, MD, is a fellow of hematology and oncology at the University of California San Diego Health.
Latest:
Dr Azenkot on Dupilumab Plus Cemiplimab in Early-Stage, Resectable NSCLC
Tali Azenkot, MD, discusses the rationale for combining dupilumab with cemiplimab in early-stage, resectable non–small cell lung cancer.
John Theurer Cancer Center, Hackensack University Medical Center
Latest:
Hackensack Meridian Health Expands Cancer Services with New Facility at JFK University Medical Center
Hackensack Meridian JFK University Medical Center has expanded its comprehensive cancer care services with the opening of a newly renovated, four-story facility at 80 James Street in Edison, NJ
Kyle Doherty
Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for
Latest:
Toripalimab Plus Chemo Maintains Survival Benefit After 6 Years in Recurrent/Metastatic NPC
The durable survival advantage seen with the regimen after 6 years of follow-up supports its use as a first-line treatment in nasopharyngeal carcinoma.